title: Small artery remodeling in diabetes mellitus.
abstract: OBJECTIVE
  To briefly review available data regarding changes in the structure of microvessels observed in patients with diabetes mellitus, and possible correction by effective treatment.
  
  
  RESULTS
  The development of structural changes in the systemic vasculature is the end result of established hypertension. In essential hypertension, small arteries' smooth muscle cells are restructured around a smaller lumen and there is no net growth of the vascular wall, while in some secondary forms of hypertension, hypertrophic remodeling may be detected. Moreover, in non-insulin-dependent diabetes mellitus hypertrophic remodeling of subcutaneous small arteries is present. Indices of small resistance artery structure, such as the tunica media to internal lumen ratio, may have a strong prognostic significance in hypertensive and diabetic patients, over and above all other known cardiovascular risk factors. Therefore, regression of vascular alterations is an appealing goal of antihypertensive treatment. Different antihypertensive drugs seem to have different effects on vascular structure. In diabetic hypertensive patients, a significant regression of structural alterations to the small resistance arteries with drugs blocking the renin-angiotensin system (ACE inhibitors, angiotensin II receptor blockers) was demonstrated.
  
  
  CONCLUSIONS
  Alterations in the microcirculation represent a common pathological finding, and microangiopathy is one of the most important mechanisms involved in the development of organ damage as well as of clinical events in patients with diabetes mellitus. Renin-angiotensin system blockade seems to be effective in preventing and/or regressing alterations in the microvascular structure.
authors.affiliation: Clinica Medica, Department of Medical and Surgical Sciences, University of Brescia, Italy. rizzoni@med.unibs.it
authors.forename: D
authors.initials: D
authors.lastname: Rizzoni
authors.forename: E Agabiti
authors.initials: EA
authors.lastname: Rosei
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001158:Arteries / Q000473:pathology / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D006965:Hyperplasia; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D008833:Microcirculation; D055806:Microvessels / Q000473:pathology / Q000503:physiopathology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology
chemical_list: D000959:Antihypertensive Agents